Multi-Cancer Screening Tests: Communicating About Risks Should be Prioritized - 04/04/22
Doi : 10.1016/j.amjmed.2021.09.012
Timothée Olivier, MD a, ⁎ 
, Jenny Gill, MS b, Vinay Prasad, MD, MPH b
, Jenny Gill, MS b, Vinay Prasad, MD, MPH b a Department of Oncology, Geneva University Hospital, Switzerland
b Department of Epidemiology and Biostatistics, University of California San Francisco, Calif
⁎Requests for reprints should be addressed to Dr. Timothée Olivier, Department of Oncology, Geneva University Hospital, 4 Gabrielle-Perret-Gentil Street, Geneva, Switzerland.Department of OncologyGeneva University Hospital4 Gabrielle-Perret-Gentil StreetGenevaSwitzerland
Le texte complet de cet article est disponible en PDF.
| Funding: This project was funded by Arnold Ventures, LLC through a grant paid to the University of California, San Francisco. |
|
| Conflict of Interest: VP discloses the following: research funding: Arnold Ventures; royalties: Johns Hopkins Press and Medscape; honoraria: grand rounds/lectures from universities, medical centers, non-profits, and professional societies; consulting: UnitedHealthcare; speaking fees: eviCore; other: plenary session podcast has Patreon backers. All other authors have no financial or non-financial conflicts of interest to report. |
|
| Authorship: All authors had access to the data and a role in writing this manuscript. |
© 2021
Elsevier Inc. Tous droits réservés.
Vol 135 - N° 4
P. 413-415 - avril 2022 Retour au numéro
Article précédent
- Antiviral Therapeutics: Key to Curbing the COVID-19 Pandemic
- Eli Y. Adashi, I. Glenn Cohen
- Physician Burnout: Fix the Doctor or Fix the System?
- Nancy C. Greep, Steffie Woolhandler, David Himmelstein
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?